<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454583</url>
  </required_header>
  <id_info>
    <org_study_id>3A-Registry</org_study_id>
    <nct_id>NCT01454583</nct_id>
  </id_info>
  <brief_title>Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany</brief_title>
  <acronym>3A</acronym>
  <official_title>3A-Register Zur Ambulanten Therapie Mit RAS-Inhibitoren in Patienten Mit Arterieller Hypertonie in Deutschland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiftung Institut fuer Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stiftung Institut fuer Herzinfarktforschung</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Germany nearly half of the population present elevated values of blood pressure, with - as
      a result of lifestyle factors and a growing average age - further increasing numbers.

      Consequences of arterial hypertension may be cardiovascular diseases, cerebrovascular events,
      and renal insufficiency. Thus, hypertension therapy focuses on the reduction of these
      complications.

      The aims of the 3A-registry are the characterization of outpatients with hypertension, their
      diagnostic procedures and medical treatment (esp. with renin inhibitors), therapy compliance
      and success, clinical events, and an assessment of overall guideline adherence in the
      treatment of these patients.

      Patients fulfilling the relevant criteria are enrolled and followed up by their general
      practitioner or medical specialist.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)</measure>
    <time_frame>baseline and 1 year</time_frame>
    <description>Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 1 year, the difference divided by the baseline value, multiplied by 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 1 year, the difference divided by the baseline value, multiplied by 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 2 years, the difference divided by the baseline value, multiplied by 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Hypertension Treatment on Diastolic Office Blood Pressure (DBP)</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 1 year, the difference divided by the baseline value, multiplied by 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 3 years, the difference divided by the baseline value, multiplied by 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 3 years, the difference divided by the baseline value, multiplied by 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapy Adherence Regarding Drug Treatment</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Percentage of patients not having changed the therapy group after 1 year (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy Adherence Regarding Drug Treatment</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Percentage of patients not having changed the therapy group after 2 years (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy Adherence Regarding Drug Treatment</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>Percentage of patients not having changed the therapy group after 3 years (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year follow up</time_frame>
    <description>Percentage of participants that experienced at least one adverse event during the first year of observation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 years follow up</time_frame>
    <description>Percentage of participants that experienced at least one adverse event during the first two years of observation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Percentage of participants that experienced at least one adverse event during the three years of observation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Relative change of ambulatory, systolic 24h BP means since baseline, i.e. 24h SBP means at baseline minus corresponding means after 1 year, the differences divided by the baseline value, multiplied by 100. Mean SBP of a patient was calculated as the arithmetic mean of automatically recorded SBP values over a contiguous period of 24 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Relative change of ambulatory, diastolic 24h BP means since baseline, i.e. 24h DBP means at baseline minus corresponding means after 1 year, the differences divided by the baseline value, multiplied by 100. Mean DBP of a patient was calculated as the arithmetic mean of automatically recorded DBP values over a contiguous period of 24 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Relative change of ambulatory, systolic 24h BP means since baseline, i.e. 24h SBP means at baseline minus corresponding means after 2 years, the differences divided by the baseline value, multiplied by 100. Mean SBP of a patient was calculated as the arithmetic mean of automatically recorded SBP values over a contiguous period of 24 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Relative change of ambulatory, diastolic 24h BP means since baseline, i.e. 24h DBP means at baseline minus corresponding means after 2 years, the differences divided by the baseline value, multiplied by 100. Mean DBP of a patient was calculated as the arithmetic mean of automatically recorded DBP values over a contiguous period of 24 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>Relative change of ambulatory, systolic 24h BP means since baseline, i.e. 24h SBP means at baseline minus corresponding means after 3 years, the differences divided by the baseline value, multiplied by 100. Mean SBP of a patient was calculated as the arithmetic mean of automatically recorded SBP values over a contiguous period of 24 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>Relative change of ambulatory, diastolic 24h BP means since baseline, i.e. 24h DBP means at baseline minus corresponding means after 3 years, the differences divided by the baseline value, multiplied by 100. Mean DBP of a patient was calculated as the arithmetic mean of automatically recorded DBP values over a contiguous period of 24 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of Anti-hypertensive Treatment on Renal Function</measure>
    <time_frame>1 year follow up</time_frame>
    <description>Improvement of the estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) by more than 2.5ml/min/1.73m², compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of Anti-hypertensive Treatment on Renal Function</measure>
    <time_frame>2 years follow up</time_frame>
    <description>Improvement of the estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) by more than 2.5ml/min/1.73m², compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of Anti-hypertensive Treatment on Renal Function</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Improvement of the estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) by more than 2.5ml/min/1.73m², compared to baseline</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">15337</enrollment>
  <condition>Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <description>Patients getting Aliskiren at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-I/ARB</arm_group_label>
    <description>Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No RAS-inhibition</arm_group_label>
    <description>Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Rasilez</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-I/ARB</intervention_name>
    <arm_group_label>ACE-I/ARB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No RAS-inhibition</intervention_name>
    <arm_group_label>No RAS-inhibition</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive outpatients with arterial hypertension and treatment with a renin inhibitor,
        ACE inhibitor, ARB, or without RAS blockade.

        In order to collect enough information on Aliskiren treatment ratio between therapy
        alternatives should be 4 (Aliskiren) to 1 (ACE inhibitor/ARB) to 1 (no RAS blockade)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  treatment as outpatient

          -  arterial hypertension

          -  treatment with a renin inhibitor, ACE inhibitor, ARB, or without RAS blockade

          -  informed consent

        Exclusion Criteria:

          -  foreseeable difficulties to perform follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Zeymer, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Stiftung Institut für Herzinfarktforschung</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <results_first_submitted>August 15, 2013</results_first_submitted>
  <results_first_submitted_qc>August 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2014</results_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renin inhibitor</keyword>
  <keyword>ACE inhibitor</keyword>
  <keyword>ARB (AT1 receptor blockers)</keyword>
  <keyword>RAS blockade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>Patients treated with Aliskiren (DRI) at baseline. In the 3rd year period, only patients with Diabetes Mellitus (DM) or Heart Failure (HF) were considered.</description>
        </group>
        <group group_id="P2">
          <title>ACE-I/ARB</title>
          <description>Patients treated with ACE-I or ARB (ARB/ACE-I) at baseline. In the 3rd year period, only patients with Diabetes Mellitus (DM) or Heart Failure (HF) were considered.</description>
        </group>
        <group group_id="P3">
          <title>No RAS-inhibition</title>
          <description>Patients treated with no RAS-inhibition drugs at baseline. In the 3rd year period, only patients with Diabetes Mellitus (DM) or Heart Failure (HF) were considered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1st Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10177">From initially 15337 pat. 351 withdrawed from the registry, 14986 pat. were assigned to the groups.</participants>
                <participants group_id="P2" count="2696"/>
                <participants group_id="P3" count="2113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9120"/>
                <participants group_id="P2" count="2378"/>
                <participants group_id="P3" count="1933"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1057"/>
                <participants group_id="P2" count="318"/>
                <participants group_id="P3" count="180"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1057"/>
                <participants group_id="P2" count="318"/>
                <participants group_id="P3" count="180"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>2nd Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10177"/>
                <participants group_id="P2" count="2696"/>
                <participants group_id="P3" count="2113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6212"/>
                <participants group_id="P2" count="1647"/>
                <participants group_id="P3" count="1376"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3965"/>
                <participants group_id="P2" count="1049"/>
                <participants group_id="P3" count="737"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3965"/>
                <participants group_id="P2" count="1049"/>
                <participants group_id="P3" count="737"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>3rd Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3791"/>
                <participants group_id="P2" count="982"/>
                <participants group_id="P3" count="582"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1832"/>
                <participants group_id="P2" count="470"/>
                <participants group_id="P3" count="285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1959"/>
                <participants group_id="P2" count="512"/>
                <participants group_id="P3" count="297"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1959"/>
                <participants group_id="P2" count="512"/>
                <participants group_id="P3" count="297"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Patients treated with Aliskiren (DRI)</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>Patients without any RAS inhibition (No-RAS-I)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10177"/>
            <count group_id="B2" value="2696"/>
            <count group_id="B3" value="2113"/>
            <count group_id="B4" value="14986"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5109"/>
                    <measurement group_id="B2" value="1300"/>
                    <measurement group_id="B3" value="1181"/>
                    <measurement group_id="B4" value="7590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5068"/>
                    <measurement group_id="B2" value="1396"/>
                    <measurement group_id="B3" value="932"/>
                    <measurement group_id="B4" value="7396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="12.06"/>
                    <measurement group_id="B2" value="63.7" spread="11.92"/>
                    <measurement group_id="B3" value="61.3" spread="13.36"/>
                    <measurement group_id="B4" value="63.3" spread="12.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4658"/>
                    <measurement group_id="B2" value="1229"/>
                    <measurement group_id="B3" value="1085"/>
                    <measurement group_id="B4" value="6972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5519"/>
                    <measurement group_id="B2" value="1467"/>
                    <measurement group_id="B3" value="1028"/>
                    <measurement group_id="B4" value="8014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)</title>
        <description>Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 1 year, the difference divided by the baseline value, multiplied by 100</description>
        <time_frame>baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)</title>
          <description>Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 1 year, the difference divided by the baseline value, multiplied by 100</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8880"/>
                <count group_id="O2" value="2321"/>
                <count group_id="O3" value="1896"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="12.5"/>
                    <measurement group_id="O2" value="9.7" spread="12.4"/>
                    <measurement group_id="O3" value="9.9" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapy Adherence Regarding Drug Treatment</title>
        <description>Percentage of patients not having changed the therapy group after 1 year (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline)</description>
        <time_frame>Baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapy Adherence Regarding Drug Treatment</title>
          <description>Percentage of patients not having changed the therapy group after 1 year (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline)</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9120"/>
                <count group_id="O2" value="2378"/>
                <count group_id="O3" value="1933"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8"/>
                    <measurement group_id="O2" value="94.9"/>
                    <measurement group_id="O3" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapy Adherence Regarding Drug Treatment</title>
        <description>Percentage of patients not having changed the therapy group after 2 years (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline)</description>
        <time_frame>Baseline and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapy Adherence Regarding Drug Treatment</title>
          <description>Percentage of patients not having changed the therapy group after 2 years (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline)</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6212"/>
                <count group_id="O2" value="1647"/>
                <count group_id="O3" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2"/>
                    <measurement group_id="O2" value="89.7"/>
                    <measurement group_id="O3" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapy Adherence Regarding Drug Treatment</title>
        <description>Percentage of patients not having changed the therapy group after 3 years (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline)</description>
        <time_frame>Baseline and 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapy Adherence Regarding Drug Treatment</title>
          <description>Percentage of patients not having changed the therapy group after 3 years (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline)</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1832"/>
                <count group_id="O2" value="470"/>
                <count group_id="O3" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8"/>
                    <measurement group_id="O2" value="82.1"/>
                    <measurement group_id="O3" value="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Percentage of participants that experienced at least one adverse event during the first year of observation period</description>
        <time_frame>1 year follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Percentage of participants that experienced at least one adverse event during the first year of observation period</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10177"/>
                <count group_id="O2" value="2696"/>
                <count group_id="O3" value="2113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Percentage of participants that experienced at least one adverse event during the first two years of observation period</description>
        <time_frame>2 years follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Percentage of participants that experienced at least one adverse event during the first two years of observation period</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10177"/>
                <count group_id="O2" value="2696"/>
                <count group_id="O3" value="2113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="6.6"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Percentage of participants that experienced at least one adverse event during the three years of observation period</description>
        <time_frame>3 years follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Percentage of participants that experienced at least one adverse event during the three years of observation period</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3791"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="582"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="12.6"/>
                    <measurement group_id="O3" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement</title>
        <description>Relative change of ambulatory, systolic 24h BP means since baseline, i.e. 24h SBP means at baseline minus corresponding means after 1 year, the differences divided by the baseline value, multiplied by 100. Mean SBP of a patient was calculated as the arithmetic mean of automatically recorded SBP values over a contiguous period of 24 h.</description>
        <time_frame>Baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement</title>
          <description>Relative change of ambulatory, systolic 24h BP means since baseline, i.e. 24h SBP means at baseline minus corresponding means after 1 year, the differences divided by the baseline value, multiplied by 100. Mean SBP of a patient was calculated as the arithmetic mean of automatically recorded SBP values over a contiguous period of 24 h.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2015"/>
                <count group_id="O2" value="532"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="10.0"/>
                    <measurement group_id="O2" value="5.9" spread="10.0"/>
                    <measurement group_id="O3" value="5.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement</title>
        <description>Relative change of ambulatory, diastolic 24h BP means since baseline, i.e. 24h DBP means at baseline minus corresponding means after 1 year, the differences divided by the baseline value, multiplied by 100. Mean DBP of a patient was calculated as the arithmetic mean of automatically recorded DBP values over a contiguous period of 24 h.</description>
        <time_frame>Baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement</title>
          <description>Relative change of ambulatory, diastolic 24h BP means since baseline, i.e. 24h DBP means at baseline minus corresponding means after 1 year, the differences divided by the baseline value, multiplied by 100. Mean DBP of a patient was calculated as the arithmetic mean of automatically recorded DBP values over a contiguous period of 24 h.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2015"/>
                <count group_id="O2" value="532"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="11.9"/>
                    <measurement group_id="O2" value="5.2" spread="11.4"/>
                    <measurement group_id="O3" value="5.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement</title>
        <description>Relative change of ambulatory, systolic 24h BP means since baseline, i.e. 24h SBP means at baseline minus corresponding means after 2 years, the differences divided by the baseline value, multiplied by 100. Mean SBP of a patient was calculated as the arithmetic mean of automatically recorded SBP values over a contiguous period of 24 h.</description>
        <time_frame>Baseline and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement</title>
          <description>Relative change of ambulatory, systolic 24h BP means since baseline, i.e. 24h SBP means at baseline minus corresponding means after 2 years, the differences divided by the baseline value, multiplied by 100. Mean SBP of a patient was calculated as the arithmetic mean of automatically recorded SBP values over a contiguous period of 24 h.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="988"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="10.7"/>
                    <measurement group_id="O2" value="6.6" spread="11.1"/>
                    <measurement group_id="O3" value="7.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement</title>
        <description>Relative change of ambulatory, diastolic 24h BP means since baseline, i.e. 24h DBP means at baseline minus corresponding means after 2 years, the differences divided by the baseline value, multiplied by 100. Mean DBP of a patient was calculated as the arithmetic mean of automatically recorded DBP values over a contiguous period of 24 h.</description>
        <time_frame>Baseline and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement</title>
          <description>Relative change of ambulatory, diastolic 24h BP means since baseline, i.e. 24h DBP means at baseline minus corresponding means after 2 years, the differences divided by the baseline value, multiplied by 100. Mean DBP of a patient was calculated as the arithmetic mean of automatically recorded DBP values over a contiguous period of 24 h.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="988"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="12.0"/>
                    <measurement group_id="O2" value="5.6" spread="14.6"/>
                    <measurement group_id="O3" value="6.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP)</title>
        <description>Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 1 year, the difference divided by the baseline value, multiplied by 100</description>
        <time_frame>Baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP)</title>
          <description>Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 1 year, the difference divided by the baseline value, multiplied by 100</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8880"/>
                <count group_id="O2" value="2321"/>
                <count group_id="O3" value="1896"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="13.0"/>
                    <measurement group_id="O2" value="7.7" spread="12.9"/>
                    <measurement group_id="O3" value="8.0" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)</title>
        <description>Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 2 years, the difference divided by the baseline value, multiplied by 100</description>
        <time_frame>Baseline and 2 years</time_frame>
        <population>Patients with RR measurement at baseline and 2 years follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)</title>
          <description>Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 2 years, the difference divided by the baseline value, multiplied by 100</description>
          <population>Patients with RR measurement at baseline and 2 years follow-up</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6055"/>
                <count group_id="O2" value="1610"/>
                <count group_id="O3" value="1345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="12.9"/>
                    <measurement group_id="O2" value="10.0" spread="13.5"/>
                    <measurement group_id="O3" value="10.4" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Hypertension Treatment on Diastolic Office Blood Pressure (DBP)</title>
        <description>Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 1 year, the difference divided by the baseline value, multiplied by 100</description>
        <time_frame>Baseline and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Hypertension Treatment on Diastolic Office Blood Pressure (DBP)</title>
          <description>Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 1 year, the difference divided by the baseline value, multiplied by 100</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6054"/>
                <count group_id="O2" value="1609"/>
                <count group_id="O3" value="1345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="13.0"/>
                    <measurement group_id="O2" value="8.5" spread="13.5"/>
                    <measurement group_id="O3" value="8.9" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)</title>
        <description>Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 3 years, the difference divided by the baseline value, multiplied by 100</description>
        <time_frame>Baseline and 3 years</time_frame>
        <population>Patients with DM or HF and RR measurement at baseline and 3 years follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)</title>
          <description>Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 3 years, the difference divided by the baseline value, multiplied by 100</description>
          <population>Patients with DM or HF and RR measurement at baseline and 3 years follow-up</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1700"/>
                <count group_id="O2" value="433"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="13.4"/>
                    <measurement group_id="O2" value="8.9" spread="14.2"/>
                    <measurement group_id="O3" value="9.4" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP)</title>
        <description>Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 3 years, the difference divided by the baseline value, multiplied by 100</description>
        <time_frame>Baseline and 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP)</title>
          <description>Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 3 years, the difference divided by the baseline value, multiplied by 100</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1700"/>
                <count group_id="O2" value="433"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="13.6"/>
                    <measurement group_id="O2" value="6.2" spread="14.2"/>
                    <measurement group_id="O3" value="6.4" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement</title>
        <description>Relative change of ambulatory, systolic 24h BP means since baseline, i.e. 24h SBP means at baseline minus corresponding means after 3 years, the differences divided by the baseline value, multiplied by 100. Mean SBP of a patient was calculated as the arithmetic mean of automatically recorded SBP values over a contiguous period of 24 h.</description>
        <time_frame>Baseline and 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement</title>
          <description>Relative change of ambulatory, systolic 24h BP means since baseline, i.e. 24h SBP means at baseline minus corresponding means after 3 years, the differences divided by the baseline value, multiplied by 100. Mean SBP of a patient was calculated as the arithmetic mean of automatically recorded SBP values over a contiguous period of 24 h.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="12.4"/>
                    <measurement group_id="O2" value="6.1" spread="11.2"/>
                    <measurement group_id="O3" value="7.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement</title>
        <description>Relative change of ambulatory, diastolic 24h BP means since baseline, i.e. 24h DBP means at baseline minus corresponding means after 3 years, the differences divided by the baseline value, multiplied by 100. Mean DBP of a patient was calculated as the arithmetic mean of automatically recorded DBP values over a contiguous period of 24 h.</description>
        <time_frame>Baseline and 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement</title>
          <description>Relative change of ambulatory, diastolic 24h BP means since baseline, i.e. 24h DBP means at baseline minus corresponding means after 3 years, the differences divided by the baseline value, multiplied by 100. Mean DBP of a patient was calculated as the arithmetic mean of automatically recorded DBP values over a contiguous period of 24 h.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="14.8"/>
                    <measurement group_id="O2" value="5.3" spread="12.4"/>
                    <measurement group_id="O3" value="6.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influence of Anti-hypertensive Treatment on Renal Function</title>
        <description>Improvement of the estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) by more than 2.5ml/min/1.73m², compared to baseline</description>
        <time_frame>1 year follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Influence of Anti-hypertensive Treatment on Renal Function</title>
          <description>Improvement of the estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) by more than 2.5ml/min/1.73m², compared to baseline</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8884"/>
                <count group_id="O2" value="2302"/>
                <count group_id="O3" value="1893"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="32.1"/>
                    <measurement group_id="O3" value="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influence of Anti-hypertensive Treatment on Renal Function</title>
        <description>Improvement of the estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) by more than 2.5ml/min/1.73m², compared to baseline</description>
        <time_frame>2 years follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Influence of Anti-hypertensive Treatment on Renal Function</title>
          <description>Improvement of the estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) by more than 2.5ml/min/1.73m², compared to baseline</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6039"/>
                <count group_id="O2" value="1600"/>
                <count group_id="O3" value="1344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="32.6"/>
                    <measurement group_id="O3" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influence of Anti-hypertensive Treatment on Renal Function</title>
        <description>Improvement of the estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) by more than 2.5ml/min/1.73m², compared to baseline</description>
        <time_frame>3 years follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Patients treated with Aliskiren (DRI)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Patients without any RAS inhibition (No-RAS-I)</description>
          </group>
        </group_list>
        <measure>
          <title>Influence of Anti-hypertensive Treatment on Renal Function</title>
          <description>Improvement of the estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) by more than 2.5ml/min/1.73m², compared to baseline</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1678"/>
                <count group_id="O2" value="429"/>
                <count group_id="O3" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="28.2"/>
                    <measurement group_id="O3" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 2 years follow up</time_frame>
      <desc>The total of affected participants refer to all patients with any SAE, regardless of event frequencies. Patients with a given SAE are only counted for SAE occurring at least 10 times in the total group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Patients treated with Aliskiren (DRI)</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Patients treated with ACE-I or ARB (ARB/ACE-I)</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>Patients without any RAS inhibition (No-RAS-I)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="649" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coronary ostial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic valve sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Chordae tendinae rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Heart alternation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Preternatural anus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ocular ischaemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ocular vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastric mucosal lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pancreatic insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Concomitant disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Drug therapeutic incompatibility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>No adverse event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Encephalitis herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Meningitis herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac valve replacement complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Implant site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QRS complex prolonged</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Angiogram</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Albumin urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Creatinine urine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arterial catheterisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood potassium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coagulation factor decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ejection fraction abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QRS complex abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Endoscopy upper gastrointestinal tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>LDL/HDL ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pathology test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>QRS axis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Urine albumin/creatinine ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Shock hypoglycaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastases to oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastases to prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Oncologic complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ovarian cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Refractory anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Apallic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Brain stem ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Carotid artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cerebral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coma hepatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Demyelination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Orthostatic intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Agoraphobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Expressive language disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Social phobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Nephroangiosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Prostatic atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bronchial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pleural disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Joint prosthesis user</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Vascular graft</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Colectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Haemodialysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Sigmoidectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Adrenalectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Bursa removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker revision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cardiac rehabilitation therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Carotid artery stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Central venous catheterisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cerebrovascular operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Eye operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Female genital operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Gastrostomy tube insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Haematoma evacuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lymphadenectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Malignant tumour excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Mechanical ventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Mitral valve repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Peripheral artery angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Phlebectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Resuscitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Therapeutic procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Tracheostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Tumour excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Macroangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Vascular compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Withdrawal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.1</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QRS complex prolonged</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2696"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Dr. Uwe Zeymer</name_or_title>
      <organization>Foundation Stiftung Institut fuer Herzinfarktforschung Ludwigshafen, Germany</organization>
      <phone>+49 621 503 2813</phone>
      <email>Uwe.Zeymer@t-online.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

